Clinical presentations of parvovirus B19 infection

American Family Physician

Volumn 75, Issue 3, 2007, Pages

  Servey, Jessica T ^a,c   Reamy, Brian V ^b   Hodge, Joshua ^a,d  

^a Uniformed Services University of the Health Sciences ^*

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c DAVID GRANT MEDICAL CENTER   (United States)

^d Malcolm Grow Medical Center Family Medicine Residency Program ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NONSTEROID ANTIINFLAMMATORY AGENT; VIRUS DNA;

ANEMIA; APLASTIC ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TRANSFUSION; CONSERVATIVE TREATMENT; ERYTHEMA INFECTIOSUM; ERYTHROCYTE; ERYTHROCYTE APLASIA; FETUS HYDROPS; GLOVES AND SOCKS SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRON DEFICIENCY ANEMIA; NONHUMAN; PARVOVIRUS; PARVOVIRUS INFECTION; SICKLE CELL ANEMIA; SPHEROCYTOSIS; THALASSEMIA;

EID: 33846936848     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Parvovirus B19 (erythema infectiosum, fifth disease). In: Red Book 2006: Report of the Committee on Infectious Diseases. 27th ed. Washington, D.C.: American Academy of Pediatrics, 2006:484-7.
2. Bell LM, Naides SJ, Stoffman P, Hodinka RL, Plotkin SA. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med 1989;321:485-91.
3. Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004;350:586-97.
4. Brown KE, Mori J, Cohen BJ, Field AM. In vitro propagation of parvovirus B19 in primary foetal liver culture. J Gen Viral 1991;72(pt 3):741-5.
5. Srivastava CH, Zhou S, Munshi NC, Srivastava A. Parvovirus B19 replication in human umbilical cord blood cells. Virology 1992;189:456-61.
6. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002;15:485-505.
7. Plummer FA, Hammond GW, Forward K, Sekla L, Thompson LM, Jones SE, et al. An erythema infectiosum-like illness caused by human parvovirus infection. N Engl J Med 1985;313:74-9.
8. American Academy of Pediatrics. Red Book Online. Accessed at: http://www.aapredbook.org.
9. Nesher G, Moore TL. Human parvovirus infection. Infect Med 1997;14:638-42.
10. Naides SJ, Scharosch LL, Foto F, Howard EJ. Rheumatologic manifestations of human parvovirus B19 infection in adults. Arthritis Rheum 1990;33:1297-309.
11. Smith-Whitley K, Zhao H, Hodinka RL, Kwiatkowski J, Cecil R, Cecil T, et al. Epidemiology of human parvovirus B19 in children with sickle cell disease. Blood 2004;103:422-7.
12. Posfay-Barbe KM, Michaels MG. Parvovirus B19 in organ transplant recipients. Curr Opin Organ Transpl 2003;8:283-7.
13. Kurtzman G, Frickhofen N, Kimball J, Jenkins DW, Nienhuis AW, Young NS. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989;321:519-23.
14. Alfadley A, Aljubran A, Hainau B, Alhokail A. Papular-purpuric "gloves and socks" syndrome in a mother and daughter. J Am Acad Dermatol 2003;48:941-4.
15. Metry D, Katta R. New and emerging pediatric infections. Dermatol Clin 2003;21:269-76.
16. Katta R. Parvovirus B19: a review. Dermatol Clin 2002;20:333-42.
17. Alger LS. Toxoplasmosis and parvovirus B19. Infect Dis Clin North Am 1997;11:55-75.
18. Morey AL, Keeling JW, Porter HJ, Fleming KA. Clinical and histopathological features of parvovirus B19 infection in the human fetus. Br J Obstet Gynaecol 1992;99:566-74.
19. American College of Obstetrics and Gynecologists. ACOG practice bulletin. Perinatal viral and parasitic infections. Number 20, September 2000. Int J Gynaecol Obstet 2002;76:95-107.
20. Institute for Clinical Systems Improvement. Prenatal care, routine. Accessed June 9, 2006, at: http://www.icsi.org/knowledge/detail.asp?catID= 29&itemID=191.
21. Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988;25:151-3.
22. Doyle S, Kerr S, O'Keeffe G, O'Carroll D, Daly P, Kilty C. Detection of parvovirus B19 IgM by antibody capture enzyme immunoassay: receiver operating characteristic analysis. J Virol Methods 2000;90:143-52.
23. Ballou WR, Reed JL, Noble W, Young NS, Koenig S. Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis 2003;187:675-8.